Abstract
The aim of this study was to compare CMR imaging biomarkers between SLE patients and matched controls. Electronic databases were systematically searched from inception until November 2023. All studies reporting CMR imaging data in SLE patients were included. PRISMA guidelines were followed, and risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale. CMR findings of SLE patients were compared to that of matched controls. Clinical features associated with CMR biomarkers were collected in a qualitative analysis. A total of 64 studies were included in the systematic review pooling 3304 individuals including 1870 SLE patients. Of these, 19 case-control studies were included in the comparative meta-analysis (1576 individuals, including 884 SLE patients). Compared to controls, left ventricular (LV) ejection fraction (62% vs. 64%, p = 0.001) and indexed end-diastolic volume (77 vs. 72 mL/m2, p = 0.006) were significantly altered in SLE patients. Late gadolinium enhancement (LGE) extent was higher in SLE patients (LGE mass/total LV mass: 3.5% vs. 1.1%, p = 0.009). Native T1 and T2 relaxation times were significantly higher in SLE patients (native T1 [1.5 T]: 1005 vs. 982 ms, p = 0.02; native T1 [3 T]: 1267 vs. 1140 ms, p < 0.001; T2 [all fields]: 58 vs. 51 ms, p < 0.001). Three studies found an association between disease activity and increased T2 relaxation times. Two studies identified an association between clinical outcomes and CMR parameters. While CMR-assessed ventricular function and volumes only slightly differed in SLE patients when compared to controls, myocardial tissue characterization parameters were significantly modified and associated with disease activity. Question What are the diagnostic and prognostic values of cardiac magnetic resonance (CMR) quantitative parameters in systemic lupus erythematosus (SLE) patients? Findings Myocardial tissue characterization parameters are significantly altered in SLE patients and associated with disease activity. Clinical relevance CMR imaging demonstrates subclinical cardiac alterations in systemic lupus erythematosus patients. Additional studies are required to further demonstrate the prognostic value of CMR in SLE.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
